

Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: efficacy and safety in CheckMate 141 by age

Supplementary Table 1

Relative dosing intensity. ^aDose units are mg/m² for IC and mg/kg for nivolumab. Abbreviation: IC = investigator's choice.

	<65 Years				≥65 Years			
	Nivolumab (n = 168)	IC (n = 71)			Nivolumab (n = 68)	IC (n = 40)		
		Cetuximab (n = 9)	Methotrexate (n = 29)	Docetaxel (n = 33)		Cetuximab (n = 4)	Methotrexate (n = 17)	Docetaxel (n = 19)
No. of doses received, median (range)	5.0 (1–70)	8.0 (3–32)	8.0 (1–18)	9.0 (1–41)	5.0 (1–72)	8.5 (8–10)	6.0 (1–17)	7.0 (1–27)
Duration of therapy, median (range)	1.9 (0–36)	1.6 (0–7)	1.9 (0–6)	2.0 (0–13)	1.9 (0–35)	1.8 (2–2)	1.6 (0–5)	1.9 (0–9)
Cumulative dose, ^a median (range)	14.9 (3–223)	2192.3 (923–8232)	280.0 (27–725)	316.6 (30–1654)	15.1 (3–232)	2345.3 (2139–2660)	244.2 (79–661)	214.6 (30–977)
Relative dose intensity, n (%)								
≥110	0	1 (11.1)	0	11 (33.3)	0	0	0	4 (21.1)
90–<110	136 (81.0)	6 (66.7)	15 (51.7)	13 (39.4)	57 (83.8)	4 (100.0)	8 (47.1)	7 (36.8)
70–<90	27 (16.1)	2 (22.2)	8 (27.6)	6 (18.2)	9 (13.2)	0	5 (29.4)	4 (21.1)
50–<70	4 (2.4)	0	2 (6.9)	3 (9.1)	2 (2.9)	0	2 (11.8)	3 (15.8)
<50	1 (0.6)	0	4 (13.8)	0	0	0	1 (5.9)	1 (5.3)
Unknown	0	0	0	0	0	0	1 (5.9)	0

Supplementary Table 2

Select treatment-related adverse events (TRAEs). Abbreviation: IC = investigator's choice.

	<65 Years				≥65 Years			
	Nivolumab (n = 168)		IC (n = 71)		Nivolumab (n = 68)		IC (n = 40)	
	Any Grade	Grade 3-4	Any Grade	Grade 3-4	Any Grade	Grade 3-4	Any Grade	Grade 3-4
Select TRAE, n (%)								
Skin	27 (16.1)	0	7 (9.9)	0	14 (20.6)	0	7 (17.5)	2 (5.0)
Endocrine	15 (8.9)	1 (0.6)	0	0	7 (10.3)	0	1 (2.5)	0
Gastrointestinal	13 (7.7)	1 (0.6)	7 (9.9)	1 (1.4)	7 (10.3)	0	9 (22.5)	1 (2.5)
Hepatic	6 (3.6)	2 (1.2)	3 (4.2)	1 (1.4)	1 (1.5)	0	2 (5.0)	0
Pulmonary	6 (3.6)	2 (1.2)	1 (1.4)	0	1 (1.5)	0	0	0
Hypersensitivity/ infusion reaction	2 (1.2)	0	2 (2.8)	1 (1.4)	1 (1.5)	0	0	0
Renal	2 (1.2)	0	2 (2.8)	1 (1.4)	1 (1.5)	0	0	0

Supplementary Figure 1

Patient disposition

